先声药业
Simcere

SIMCERE PHARMACEUTICAL GROUP LIMITED

2022 R&D DAY

STOCK CODE: 2096.HK

DISCLAIMER

These presentation materials have been prepared by Simcere Pharmaceutical Group Limited 先聲藥業集團有限公司 (the "Company") in accordance with the prevailing econ
information only. It should be understood that any subsequent development could affect the information contained in such presentation materials and that the Company, the
representatives shall not be obliged to make any revision, amendment or update with respect to such information. It is in summary form and does not purport
regarding the securities of the Company (the "Securities").

The information contained in these presentation materials has not been reviewed by any regulatory authorities, and has not been independently verified. The Company
these presentation materials to contain a complete, accurate or comprehensive analysis of the financial or trading position or prospects of the Company. The Company
affiliates, directors, supervisors, officers, employees, agents, advisors or representatives shall make no express or implied representation, warranty or undertaking as
as to the accuracy, reliability, completeness, fairness
omic, legal, market and other conditions and for
to be complete, nor does it constitute a recommendation
ces not intend to provide, and you should not rely on

AGENDA

01 Welcome Speech

Ren Jingsheng
Chairman of the Board & CEO

5min

02 Company Overview Strategy

Zhou Gaobo
CIO

10min

03 Pre-clinical R&D Update

EVP

20min

04 Late-stage Oncology Pipeline

Bijoyesh Mookerjee , MD
CMO， Oncology

20min

05 Late-stage Non-oncology Pipeline

Danny Chen , PhD
SVP, neuroscience

20min



06 Strengthening BD, M&A and Investments within a Global Strategy

ver , PhD
SVP, Global Head of BD&L

10min

07 Q&A - ALL

HOST : Jason Bao
Secretary of the Board

Company Overview Strategy

Zhou Gaobo
CIO

Fundamentals of our business driven by extensive unmet clinical needs in China and beyond

Forecast of global patient population in 2030: China, EU, US (10,000 people)



Note:
CNS diseases: AD, Schizophrenia, Dysthymia, Depermentia, BD, Epilepsy, Cerebral Stroke, PD;
Autoimmune diseases: RA, AS, Psoriasis, SLE, Gout, Sjögren's Syndrome, Atopicdermatitis, UC,

GD and CCI

Source: analysis of World Bank and Silicon Valley Bank, data of G

Biopharma innovation flourishing in China while bottlenecks also emerging —— industry entering innovation 2.0 era

d crowding limit quality of

Biopharma innovation driven by growth patient needs,

Intense competition and



pharmaceutical company



Innovative and competitively differentiated products contribute to 60%+ of Simcere's revenue

Share of innovative products in total revenue

45.1%

32.9%

Sanbexin®

The only newly approved stroke drug globally since 2015

Entered 2,400 hospitals in first year of launch

100+%. growth annually, major contributor to CNS portfolio

ENWEIDA (Envafolimab)

Global first subcutaneous PD-L1

COSELA (Trilaciclib)

First-in-class comprehensive myelo-protective therapy

2021.11.25
Approved

2,000 patients treated

2021.11.29
NDA priority review by NMPA

Full value chain capabilities enable Simcere's innovation aspiration



Accelerating towards innovation through in-house R&D and partner collaboration

Local innovation capabilities



Track record as partner of choice

Sustained R&D investment for future growth

R&D Spending Ratio

R&D Talent Pool



employees

950 +

advanced degree

> 60 %

Seasoned team with global vision



Sustained high quality growth driven by key innovative products

Projected share of innovative products in total revenue



Peak sales (USD)

Sanbexin®	$800 M
Sublingual tablet	
ENWEIDA®	$400 M
Trilaciclib	$400 M
Sevacizumab	$250 M
Endostar®	

Key developments expected in 2022

Joining the fight against COVID-19

Oral 3CL inhibitor

Rapid clinical advancement in China and abroad

New Product Launch

Trilaciclib (ES-SCLC)

First-in-class new drug expect

Expansion of key product

Sapacitabine sublingual tablet

Comm

continue to ramp up rapidly

Highlights

chemotherapy, the product has the potential of gaining huge market share and attention.

achieved annual sales of RMB 1.5 billion in its first year. The rapid clinical development of Sanbaxin a multi-mechanism full-course therapeutic approach.

in early April.

Innovation Simcere has formed **a new drug R&D pipeline of nearly 60 projects**, with 20 projects in clinical st involving 17 potential innovative drugs.

Globalization internationalized organization and talent pool etc.

Preclinical Drug R&D

Tang Renhong, PhD

EVP

Preclinical R&D Strategy and Drug Discovery Engines

Patient-Centric Drug Discovery Strategy

clinical needs of patients as the core R&D goals

through both internal R&D and external collaboration

- Delivering value to global patients

Growing Portfolio with Strong long-term Potential

- Research Delivered 17 Molecules to the Clinical in less than 5 years

Proprietary platform

Simcere Creative platform of Protein Engineering

Adopting AI in Drug Discovery

- Focus on the application on early stage drug discovery, such as hit generation and optimization
- Establishing data science infrastructure and capability internally
- Collaborating with external partner for agile development

Project Y – Our Path to the Future

focusing on exploring and creating

…to attract and unite a group of young talents in life science and f

th either high treatment needs or

drug discovery

10 directions/technologies wi
breakthrough potential

fill the gap during the transformation of research hypothesis to therapeutics development

Building the true innovative research engine

Diseases-Specific Strategies and key Assets

Oncology

, Female reproductive, Hematological malignancy

Building Depth on prioritized tumor types: Lung, Breast, GI



SIM0348: TIGIT/PVRIG Bispecific Antibody

Dual Checkpoint targeting for enhanced T cells stimulation



y Effect With Tecentriq



- Simultaneously targeting two checkpoints for improved immune activation

Significant Synerg



- 60% Tumor growth inhibition achieved in PD-L1 blocker insensitive model

SIM0237: PD-L1/IL15v Bifunctional Fusion Protein

Best-in-Class potential with Improved tumor control and low safety risk

Rationale:

- Blocking PD-1/PD-L1 signaling and deliver IL-15 directly to TME for fully activation of CD8 T cells
- Fine tune IL-15 pharmacological profile through protein engineering



Significant Tumor Growth Inhibition



SIM0217: First-in-Class RAD51 inhibitor

Significant advantages on efficacy, safety , developability compared to current leading competitor

o Efficacy



- RAD51 plays a central role in the homologous recombination pathway
- Overexpressed in several human malignancies, correlates with poor prognosis
- Synthetic lethality with ATR overexpressed tumors

Multiple combination potential with chemotherapy and other DDR pathway targeting therapeutics

Superior In Vitro Activity And In Viv



Broad combination opportunities for multiple tumor types



lethal potential to microsatellite instability (MSI)

ning supported by machine learning algorithm

- Target plays a pivot role in mismatch repair (MMR) with synthetic
- Current no publicly disclosed inhibitor yet
- Successful identification of Hit compound through virtual lib scree



Autoimmunity



- Re-establish Treg/Teffs balance

- Minimizing the systemic side-effects

SIM0278：IL-2 mutein specifically Promote Treg Function

Differentiation through protein engineering



Ab-Steroid conjugate for Th2 suppression

Significant decrease of IgE production and inflammatory cell infiltration bring great histological improvement



Neuroscience

Strengthening our core competence in stroke, expand to neurodegenerative Diseases

Stroke

- Whole disease course management
- co-morbidities control through new MoA/Modalities
- Hemorrhagic Stroke expansion



Neurodegenerative Diseases

- Combination of multiple mechanisms for early intervention
- Inhibit neurocytotoxic protein aggregation
- Neuroimmu

Expand Sanbexin® to Hemorrhagic Stroke

Collagenase-induced intracerebral hemorrhage Model



Subarachnoid Hemorrhage Model









SIM0417: Inhibitor of COVID-19 3CL

Oral 3CL protease inhibitor jointly developed with Shanghai Institute of Materia Medica

2021.11.17	2022.03.28	2022.04.10	2022 Q3	Phase 2/3 trials
Collaboration with SIMM				

Phase 1 FIH

IND Approval

Part A: Single-dose of SSD8432 and SSD8432 co-administrated with Ritonavir
Part B: Multiple-dose of SSD8432
Part C: Multiple-dose of SSD8432 co-administrated with Ritonavir



- **Good Antiviral Activity** great antiviral activity against wild-type, delta and Omicron strain, inhibit viral replication in lung and brain tissue, significantly improve lung damage caused by the virus.
- **Excellent *in vivo* Pharmacokinetic Properties** SIM0417 has good pharmacokinetic properties *in vivo*, its lung tissue exposure is higher than that of ... has a lower human plasma protein binding ratio ...
- **Good Safety Margin** verified by ... GLP tox. **No** genotoxicity.

Simcere 先声药业

Expected submissions in 2022



Key Takeaways for Today

1 Patient-centered principle is core of our drug R&D efforts

2 Build competence in platform technology to create competitive advantages

3 Improve TA-focused strategy through deeper understanding of disease biolog

4 Quick and agile execution of high potential assets for clinical validation

5 Establish solid foundation of next-gen innovation through Project Y for long-term growth

Late-stage Oncology Pipeline

Bijoyesh Mookerjee, MD
Chief Medical Officer

Oncology Clinical R&D Strategy

Focus on innovation to maximize impact on patients



Therapeutic Area Layout

y for cancer patients in China

Clinical value-oriented medicines to provide greater efficacy

Simcere anti-tumor products approved for

Estimated incident rates of new cancers (China)



Oncology Pipeline Layout

Maximize existing, and accelerate new medicines and combinations



Key Project Introduction

Progress in Clinical Trials

Trilaciclib: a CDK4/6 inhibitor that provides prophylactic bone marrow protection

Protects **hematopoietic stem/progenitor cells (HSPCs)** from chemotherapy and enhance the immune system through

Prevent multiple adverse events of myelosuppression through multilineage bone marrow protection[1-3]

Mitigate neutropenia

avoid administration delay and





Enhance immune response and protect immune function

- Change the proliferation kinetics and composition of T cell subsets in tumors to enhance the number and

Pipeline-in-a-Molecule Opportunity Beyond ES-SCLC Launch



1L CRC data readout in 1Q 2023 expected to include results for myeloprotection and Objective Response Rate (ORR) endpoints
1L TNBC data readout in 2H 2023 now reflects to include interim results for Overall Survival (OS)

Trilaciclib: accelerating the indication process in China

Only FDA-approved therapy that proactively delivers multilineage myeloprotection to extensive stage SCLC patients being treated with chemotherapy

2021/2/12

On 12 February 2021, FDA fully approved **COSELA™ (Trilaciclib)** for bone marrow protection in ES-SCLC patients, which is **the world's first and only** bone marrow protection therapy that can reduce the incidence of chemotherapy-induced myelosuppression

2021/11/29

Submission of Conditional Marketing

TRACES study in China:

Phase III trial for ES-SCLC treated with 1-3L chem

- The 1st part: safety lead-in and PK bri
- benefit trend consistent with those in
- The 2nd part: placebo controlled, prim
- Conditional marketi

otherapy (N=92)

dging, primary analysis completed, PK and

overseas countries

ary endpoint met (DSN* in the first cycle).

ng application submitted to China NMPA in November

*DSN: duration of severe neutropenia

Trilaciclib: PRESERVE trials



Phase III global clinical trial for bone marrow protection in CRC patients treated with FOLFOXIRI & Bevacizumab (N=296)

- **Primary Endpoint: Duration of severe neutropenia in cycle 1 and occurrence of severe neutropenia during Induction**
- **FPI worldwide: 16 October 2020**
- **FPI in China: 24 September 2021**

PRESERVE 2 : TNBC (N=170)

- **Primary endpoint: Overall Survival**
- **FPI worldwide: 15 April 2021**
- **FPI in China: 7 January 2022**

Trilaciclib showed strong OS improvement in the TNBC randomized controlled phase II trial.

In July 2021, TNBC indication was granted Fast Track designa

Endostar® New Indication: malignant thoracoabdominal effusions

tar® also has a
nt thoracoabdominal
effusions[1]

Early studies have shown that Endos
positive therapeutic effect on malign

a recombinant human endostatin injection
-line treatment of advanced NSCLC in China

Endostar® is
approved for first

Shukui Qin, etc. Chinese Clinical Oncology, 2017

Endostar® New Indication: COREMAP study

ominal effusions

To address the urgent need of patients with malignant thoracoabdo

- Among patients with incurable tumors whose expected survival is longer than two weeks, the proportion of abdominal distension caused by ascites and other reasons is as high as 29% (meta analysis).
- According to Frost & Sullivan data, the incidence of intracavitary malignancy reached 707,900 in 2019 and is estimated to increase to 756,900 by 2030.

Tumors causing malignant thoracoabdominal effusions



Tumors causing malignant thoracoabdominal effusions



COREMAP ： Endostar® for treatment of malignant thoracoabdominal effusions, phase III

CHINA

Intra-pleural injection of recombinant human endostatin/placebo with cisplatin in treatment of malignant thoracoabdominal effusions: a multicenter, randomized,

- **FPI: 28 July 2021**
- **Recruitment：105 subjects enrolled as of March 30,2022**
- **Interim results analysis expected in H2 2022**

Shukui Qin, etc. Chinese Clinical Oncology, 2017

great potential[2]

- Clinical trials underway in other forms of brain cancer beyond GBM: DIPG, primary CNS lymphoma, brain metastases.
- Potential to combine with chemotherapy, radiotherapy and targeted drugs (e.g,. EGFR inhibitors).
- Potential to target non-brain cancers: Breast cancer, NSCLC, CRC, endometrial cancer, GIST, pancreatic cancer, RCC, TCC, HNSCCs, GBM, leukemia, melanoma, and NHL

12-15 months

average survival with treatment

~65%

main treatment drug is **...ozolomide**

...na's annual market size for ...M is about **2B yuan**

...ozolomide **almost ineffective** ...**65%** of the patients (those with ...ethylated MGMT status)



Glioblastoma (GBM)

133,000 cases per annum worldwide

BM indication, Orphan Drug designation was granted

- For the G

Envafolimab

First PD-L1 Antibody Approved For Subcutaneous Injection



- Envafolimab has a good safety profile, as a single agent
- Envafolimab phase II trial for advanced MSI-H/dMMR solid tumor showed it ... [illegible] ... NDA ... submitted to NMPA in December 2020 and approved in November 2021

2020 CSCO	N	ORR	DCR	12moPFS	12mo OS
Total	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
Advanced ... Treatment ... 3 drugs	[illegible]	[illegible]	[illegible]	[illegible]	[illegible]
Treatment failure after 2 drugs	24	62.5%	66.7%	62.5%	87.1%
Advanced GC	[illegible]	44.4%	[illegible]	[illegible]	[illegible]
Other solid tumors	20	40.0%	65.0%	[illegible]	75.0%

- Novel humanized dAb against PDL1
- Low immunogenicity
- Stable

1.2020 CSCO

Envafolimab and Anti-angiogenic Combinations

Envafolimab + Sevacizumab

Phase II trial of Envafolimab combination therapy in solid tumor patients

- **Indications of the combination therapy**
- **Using Simcere Diagnostics TSO500 Kit, benchmarked against FoundationOne® CDx.**



Clinical study led by collaborator 3D Medicines

SIM0235： Humanized anti-TNFR2 monoclonal antibody

New targets for tumor immunity

pproved (1st in same target)

US IND approved

China IND ap

Exploring the development potential of single agents in solid tumors and



cell surface:

ndogenous TNF, it

TNFR2-mediated immunosuppression and tumor cell

ation.

y-dependent cell-mediated cytotoxicity (ADCC) mediated

erminal has a direct killing effect on immunosuppressive

cluding tumor cells expressing TNFR2, regulatory T cells

and bone marrow-derived suppressor cells (MDSCs).

TNFR2 Humanized Animal Model: Single Drug Efficacy



Animal Model Data: Combination with Anti-PD-L1 Antibody



It can specifically recognize TNFR2[1,2,3] on the

• By blocking the activation of TNFR2 by e

affects

prolifera

• Antibod

by Fc te

cells, in

(Tregs)

1.Williams GS et al., Oncotarget. 2016;2.Vanamee E et al., Trends in Molecular Medicine.

SIM0270: BBB permeable, tumor tissue-enriched,



Milestones 2021-2022



Note: SCLC: small-cell lung cancer, CRC: colorectal cancer, TNBC: triple negative breast cancer, OS: overall survival, ER: estrogen receptor

Operational Excellence Driving Simcere's Purpose and R&D Vision



Operational Excellence— New Asset Development

FPI in China (SCLC)

126d

2021.5.25

Globalization to Further Extend Asset Value

Providing Today's Patients with Medicines of the Future




Late-stage Non-oncology Pipeline

Danny Chen , PhD
SVP

Overall Strategy

Focus on targets and disease of high unmet needs

China and globally

- Develop novel FIC compounds alone and in combination to further improve treatment outcome in AIS and haemorrhagic stroke

Limitations of current treatment

- Focus on rheumatology and dermatology
- Innovative MoA and products

Summary

CNS/Autoimmune clinical strategies and highlights – clinical value and differentiation

Non-oncology Pipeline

CNS, Autoimmune, and the disease areas that have significant clinical needs in the future



Key Project Introduction

CNS

CNS Clinical Focus

Subsegments of nervous system disease

Neurological drug R&D success	Few domestic	Both China-unique and

China's Stroke Treatments Still Have Huge Challenges

Large Number Patients And Low Thrombolytic Rate

Number of Discharged Patients with Ischemic and Hemorrhagic Stroke in China 2005-2019[1]

(10000 person)



About [illegible] of ischemic stroke patients missed IV thrombolysis treatment window due to hospitalization later than 6h from onset.

	China	US
Proportion of patients receiving rt-PA within 3 hours of onset[2]	18.3%	83.6%

Average thrombolytic rate



Ischemic Stroke Patients 5-year Recurrence Rate[3-4] 41%

1. China Health Statistics Yearbook 2020
2. DOI: 10.3760/cma.j.cn112137-20210416-00914.
3. The lancet global health 10.1016/S2214-109X(20)30069-3
4. China cardiovascular health and disease report 2020

48 clinical centers across the country participated in the trial, including ~1200 subjects, and the data were

of patients with

atment.

Primary efficacy endpoint: Proportion o

mRS score ≤ 1 on day 90 of tre

The only journal of the American Stroke Association

OR:1.42， 95%CI:1.12~1.81, **P =0.0004**



Sanbexin®: TASTE II Ischemic Stroke Reperfusion Study

Planning to enroll over 1300 subjects, across nearly 80 clinical centers in China

- A phase IV study to evaluate the efficacy and safety of Sanbexin combined with early endovascular recanalization therapy in patients with Acute Ischemic Stroke (AIS)
- March 18, 2022： FPI
- Complete 80% enrollment expected in 2023

TASTE-2

After vascular recanalization, Sanbexin can directly enter the ischemic site to promote the recovery of ischemic damaged brain tissue

Protect the brain tissue from re-injury caused by ischemia-reperfusion injury

The efficacy of new neuroprotective agent edaravone dexborneol combined with alteplase on AIS

Sanbexin®: Hemorrhagic Stroke Indication

Preclinical study

Animal experiments showed that Sanbexin® could significantly improve the prognosis of cerebral hemorrhage.

- Sanbexin® administration two hours after the onset of collagenase-induced ICH co significantly relieve the cerebral edema caused by hemorrhagic stroke.
- Sanbexin® could significantly improve the permeability of blood brain barrier after cerebral hemorrhage.



the treatment of cerebral hemorrhage

- The trial will be launched in the end of 2022.
- N≈300



Sanbexin Sublingual Tablet

To further expand the effectiveness of Sanbexin in stroke treatment and recovery



Sanbexin Sublingual Tablet

Phase III clinical study in the treatment of acute ischemic stroke

pportion of participants with mRS≤1 on day90 of treatment

Primary endpoint: pro



Whole course management of stroke (N=914)

- June 28, 2021, the first case of the subject's delivery
- December 31, 2021, achieving the enrollment of 519 subjects, exceeding expectations
- March 12, 2022, 783 subjects were enrolled
- Interim analysis expected in 2022H1, and complete

Phase I clinical trial in China

- IND approval: April 2021
- FIH: December 2021
- Phase I co

Stroke Pipeline Layout

Ischemic stroke	Hemorrhagic stroke	Cerebral edema
Sanbexin® Sanbexin® Sublingual Tablet PSD-95	Sanbexin®	SIM0307 (AQP4)

Early/long-term intervention based on a combination of multiple mechanisms

- 01 Reduce neuroinflammation
- 02 Prevent cerebral edema
- 04 Improve neuronal survival

SIM0408: Targeting A Key Catalytic Enzyme in Neurotoxic Aβ Aggregate Formation

QPCT oral small molecule inhibitor



Key Project Introduction

Autoimmune

Iremod® New Indication: Siogren's Syndrome

The efficacy and safety for RA have been verified for over 10 years



Lizhanguo team. EULAR. Ann Rheum Dis, 2019, 78 (suppl 2): A1696 (No.AB0465)
https://doi.org/10.3389/fphar.2021.621208

Iremod® New Indication: Sjögren's Syndrome

Digestive problems | Muscle pain | Vaginal dryness | ...vous system disorders

Lack of effective clinical drugs

In April 2020, Iremod entered the "China Standard for the Diagnosis and Treatment of Primary Sjögr...

...y 20, 2022 | ...ll achieve by the end of April

2022 plan

Completion of Phase II clinical results readout and initiation of Phase III clinical studies

LNK01001： Selective Jak1 Inhibitor

March 18, 2022, Simcere entered into a collaboration agreement with Lynk Pharmaceuticals to obtain the exclusive commercialization interest of LNK01001 for rheumatoid arthritis (RA) and Ankylosing spondylitis (AS) indications in China. Lynk Pharmaceuticals will be responsible for the clinical development of LNK01001.

LYNK PHARMACEUTICALS

ubjects
d tolerability

EAE above >2 or higher during the trial;
AE;
eath-causing TEAE;
EAE leading to discontinuation;
al
olism and elimination of LNK01001;
ficantly with fasting or eating
elationship (pSTAT Inhibition assay)

Phase 1 PK and PD summary:

- **SAD:** PK parameters increase proportionally in the range of 6 mg to 84 mg along with the dose.Exposure in vivo to LNK01001 AUC and Cmax are linearly kinetic.
- **MAD:** AUCs with multiple administrations on D1 & D7: basically consistent; basically, no accumulation in the body
- No dose-related incidence of adverse events
- **FE:** AUC shows no significant change with fasting or eating state; postprandi administration has no significant effect on the metab elimination of half life period(T1/2) Not change signi
- PD: good Pharmacokinetic and Pharmacodynamic

Phase I studies in healthy su demonstrats good safety an

- No TE
- No SA
- No de
- No TE

Milestones Expected in 2022

Iremod® (Sjogren's syndrome)

Result summary of phase II; Regulatory communication before phase III

SIM0417(3CL)

Orally Administered SSD8432 COVID-19 Treatment, phase I & phase II/III
Phase I, CSR
Phase II/III, FPI

Sanbexin®(Cerebral hemorrhage)

Hemorrhagic stroke as a newly added indication of

SIM0408(QPCT)

(international multicenter)
FPI

Sanbexin®(Reperfusion)

ombined with reperfusion for AIS treatment, phase IV
Achieve the enrollment goal

Sanbexin Sublingual Tablet

Y-2 for AIS treatment, phase III

SIM0307（AQP4）

Acute severe ischemic stroke complicated with cerebral edema, phase I, CSR

SIM0335

CKBA for treatment of mild to moderate psoriasis, phase II
FPI, LPI

SIM0278

IL-2 for treatment of systemic lupus Erythematosus
FDA IND

Strengthening BD, M&A and Investments within a Global Strategy

Kevin Oliver , PhD
SVP, Global Head of BD&L

Simcere's BD/M&A Team has high credibility, is diverse and has a deep reputation in the industry

50+

acquisitions integrated collective experience

2018、2019、2020

Professional (ASAP) Excellence Awards

30

FTEs

25

TRANSACTIONS

Caobo Zhou,
CIO, Head of BD&I, AP
McKinsey & Company

Michael Bayewitch
ED, US AP Transactions
teva

Kevin Oliver
SVP Global Head of BD&I
MERCK · NOVARTIS · Alcon

Yuchua Gong
ED Head of BD&I, EU
Estar · POLYTHERICS

Yves McMullen
Head of US Transactions and Global Invest

S&E

LEGAL

AM

Affairs, US, EU
BOSTON BIOMEDICAL

Mark Coflin
VP Global Alliance Management

Catherine Abbadie
Global Head of CNS S&E

Matthias Höss
Global Head of Autoimmune

Markus Decker,
Global Head, Oncology S&E

Ian Liu
Head of Legal & Gov't A
FOSUN信星 · BREAS

先声药业

BD is geographically established to become ‘Partner of Choice’



Global operation, centered in Boston, will focus on six key, global operational strategies

Platforms as innovation driver

Global clinical center of excellence

High return of investment

Operational excellence

Open business development: Clinical/Academic/Pharma

Academic partnership to drive innovation

Simcere

People, Integrity, Trust and proven Capabilities are critical to being ‘Partner of Choice’



Simcere values its existing 35+ alliances and IP positions



(Abatacept),
in China

Strategic partner
Exclusive commercialization of Olmetec Plus® (Olmesartan medoxomil, Hydrochlorothiazide) in China

Collaborate withthe second largest pharmaceutical company in Korea to develop new drug for gout in China

Partnership to develop novel antiviral drugs for COVID-19

Co-development of Orencia®
a blockbuster drug for RA

Strategically driven BD: In-licensing interests in Oncology

g screening

(Novel

n-licensing/Co-dev, R&D
nvestment, M&A)

Small molecule and biologics

Focus on high unmet need indications that are TOP10 prevalent tumor types in China

s with First-in-class and/or Best-in-

Novel drug classes/modalities (RNA therapeutics, Tetra-

First-in-class

relationships that lead to global licensing rights and an engine to feed the pipeline

Late / commercial stage M&A

Innovative modalities

High-throughput structure-based drug
(Challenging Targets)

Novel drug targets

(preferred)

Novel ex-vivo functional screening platforms
types of SL interactions)

Flexible partnership models (I
collaborations, JV & Equity In

Strategically-driven BD: In-licensing interests in CNS and Autoimmune

Autoimmune

Indications with immune-mediated pathology and high unmet need in China

Current focus on rheumatology and dermatology

General

Focus on high unmet medical need in China

Later stage assets with clinical PoC in relevant indications

Earlier stage assets (≥ late preclinical) with innovative mechanisms need to have potential to deliver highly differentiated patient benefit

Flexible partnership models (In-licensing/Co-dev, R&D collaborations, JV & Equity Investment opportunities)

CNS

Neurology: Focus on Stroke

Exclusive License Agreement for Trilaciclib in Greater China

2020.11.18(SCLC)
IND for leading

2021.11.29
(SCLC)

Exclusive License Agreement for small molecule, PQ912, and biologic in Greater China

2020 2021 2022

2020.06.29
Established collabration

2021.12.14
IND submission

2022.5

2022.7
Phase II (MRCT) - FPI

oval

3pE Amyloid-Targeting Medicines to Treat
s Disease.

acy, among available clinical opportunities

s

Phase 2 N3
Alzheimer's

patient



3DMed Alphamab Exclusive License Agreement for Envafolimab in Mainland China

康宁杰瑞 ALPHAMAB ONCOLOGY

2020.12.17
BLA submission to NMPA

2021.12.3
First prescription

2020 2021

BLA approval

Established collabration

the world

First PD-L1 developed by Chinese in China

First subcutaneous injection in PD-L1 category around

Simcere as Partner of Choice in China… with global ambitions

Q & A

ATTENDEES

HOST :

先声药业
Simcere

SIMCERE PHARMACEUTICAL GROUP LIMITED

2022 R&D DAY

STOCK CODE: 2096.HK

IR CONTACTS